Plasmid DNA was key to the development of biologic drug manufacturing. Today, it plays a critical role in the production of next-generation cell and gene therapies and vaccines. With its plasmid DNA manufacturing expertise, Aldevron has helped facilitate the advance of these important therapeutics. The company continues to invest in additional capacity and novel capabilities to support biopharma manufacturers into the future.

Aldevron today announced it ranked 287 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America now in its 26th year. Aldevron’s growth surpassed all expectations during this period.

Aldevron, a global leader in the manufacture of plasmid DNA, mRNA and proteins, today announced Shawn McCormick as its Chief Financial Officer. He will begin this new role immediately and will be a member of Aldevron’s executive team reporting to CEO Kevin Ballinger.